Although allogeneic hematopoietic stem cell transplantation (HSCT) is a curative approach for many pediatric patients with hematologic malignancies and some nonmalignant disorders, some critical obstacles remain to be overcome, including relapse, engraftment failure, graft-versus-host disease (GVHD), and infection. Harnessing the immune system to induce a graft-versus-tumor effect or rapidly restore antiviral immunity through the use of donor lymphocyte infusion (DLI) has been remarkably successful in some settings. Unfortunately, however, the responses to DLI can be variable, and GVHD is common. Thus, manipulations to minimize GVHD while restoring antiviral immunity and enhancing the graft-versus-tumor effect are needed to improve outcomes after allogeneic HSCT. Cellular therapies, defined as treatment modalities in which hematopoietic or nonhematopoietic cells are used as therapeutic agents, offer this promise for improving outcomes post-HSCT. This review presents an overview of the field for pediatric cell therapies in the transplant setting and discusses how we can broaden applicability beyond phase I.

Will post-transplantation cell therapies for pediatric patients become standard of care? / Lankester, A. C.; Locatelli, F.; Bader, P.; Rettinger, E.; Egeler, M.; Katewa, S.; Pulsipher, M. A.; Nierkens, S.; Schultz, K.; Handgretinger, R.; Grupp, S. A.; Boelens, J. J.; Bollard, C. M.. - In: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. - ISSN 1083-8791. - 21:3(2015), pp. 402-411. [10.1016/j.bbmt.2014.07.018]

Will post-transplantation cell therapies for pediatric patients become standard of care?

Locatelli F.;
2015

Abstract

Although allogeneic hematopoietic stem cell transplantation (HSCT) is a curative approach for many pediatric patients with hematologic malignancies and some nonmalignant disorders, some critical obstacles remain to be overcome, including relapse, engraftment failure, graft-versus-host disease (GVHD), and infection. Harnessing the immune system to induce a graft-versus-tumor effect or rapidly restore antiviral immunity through the use of donor lymphocyte infusion (DLI) has been remarkably successful in some settings. Unfortunately, however, the responses to DLI can be variable, and GVHD is common. Thus, manipulations to minimize GVHD while restoring antiviral immunity and enhancing the graft-versus-tumor effect are needed to improve outcomes after allogeneic HSCT. Cellular therapies, defined as treatment modalities in which hematopoietic or nonhematopoietic cells are used as therapeutic agents, offer this promise for improving outcomes post-HSCT. This review presents an overview of the field for pediatric cell therapies in the transplant setting and discusses how we can broaden applicability beyond phase I.
2015
adoptive cellular therapy; chimeric antigen receptor; pediatrics; stem cell transplantation
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Will post-transplantation cell therapies for pediatric patients become standard of care? / Lankester, A. C.; Locatelli, F.; Bader, P.; Rettinger, E.; Egeler, M.; Katewa, S.; Pulsipher, M. A.; Nierkens, S.; Schultz, K.; Handgretinger, R.; Grupp, S. A.; Boelens, J. J.; Bollard, C. M.. - In: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. - ISSN 1083-8791. - 21:3(2015), pp. 402-411. [10.1016/j.bbmt.2014.07.018]
File allegati a questo prodotto
File Dimensione Formato  
Lankester_Will Post-Transplantation_2015.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 601.28 kB
Formato Adobe PDF
601.28 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1480288
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 7
social impact